Krebs Biochemicals & Industries Limited
Fundamental Score
Krebs Biochemicals & Industries Limited Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of KREBSBIO across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Balanced Promoter Holding (72.74%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
10 factors identified
Suboptimal ROCE (-30.09%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Margin Pressure Concerns (-35.14%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Revenue Contraction (-67.57%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Weak Earnings Growth (4.02% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (1.23% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Weak Interest Coverage (-3.19x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Negative Free Cash Flow (₹-132.65 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Limited Institutional Interest (FII+DII: 0.50%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Krebs Biochemicals & Industries Limited
About KREBSBIO
Business Overview
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is based in Visakhapatnam, India.
Company Details
Key Leadership
Corporate Events
KREBSBIO Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Krebs Biochemicals & Industries Limited (KREBSBIO)?
As of 29 Jan 2026, 10:34 am IST, Krebs Biochemicals & Industries Limited (KREBSBIO) is currently trading at ₹60.85. The stock has a market capitalization of ₹141.35 (Cr).
Is KREBSBIO share price Overvalued or Undervalued?
KREBSBIO is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.
What factors affect the Krebs Biochemicals & Industries Limited share price?
Key factors influencing KREBSBIO's price include its quarterly earnings growth (Sales Growth: -67.57%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Krebs Biochemicals & Industries Limited a good stock for long-term investment?
Krebs Biochemicals & Industries Limited shows a 5-year Profit Growth of 1.23% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of N/A before investing.
How does Krebs Biochemicals & Industries Limited compare with its industry peers?
Krebs Biochemicals & Industries Limited competes with major peers in the Pharmaceuticals. Investors should compare KREBSBIO's P/E of 0.00x and ROE of N/A% against the industry averages to determine its competitive standing.
What is the P/E ratio of KREBSBIO and what does it mean?
KREBSBIO has a P/E ratio of N/Ax compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.
How is KREBSBIO performing according to Bull Run's analysis?
KREBSBIO has a Bull Run fundamental score of 11.4/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does KREBSBIO belong to?
KREBSBIO operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Krebs Biochemicals & Industries Limited.
What is Return on Equity (ROE) and why is it important for KREBSBIO?
KREBSBIO has an ROE of N/A%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Krebs Biochemicals & Industries Limited generates profits from shareholders' equity.
How is KREBSBIO's debt-to-equity ratio and what does it indicate?
KREBSBIO has a debt-to-equity ratio of N/A, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is KREBSBIO's dividend yield and is it a good dividend stock?
KREBSBIO offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has KREBSBIO grown over the past 5 years?
KREBSBIO has achieved 5-year growth rates of: Sales Growth 5.33%, Profit Growth 1.23%, and EPS Growth 4.02%.
What is the promoter holding in KREBSBIO and why does it matter?
Promoters hold 72.74% of KREBSBIO shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is KREBSBIO's market capitalization category?
KREBSBIO has a market capitalization of ₹141 crores, placing it in the Small-cap category.
How volatile is KREBSBIO stock?
KREBSBIO has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for KREBSBIO?
KREBSBIO has a 52-week high of ₹N/A and low of ₹N/A.
What is KREBSBIO's operating profit margin trend?
KREBSBIO has a 5-year average Operating Profit Margin (OPM) of -35.14%, indicating the company's operational efficiency.
How is KREBSBIO's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -67.57% and YoY Profit Growth of -6.60%.
What is the institutional holding pattern in KREBSBIO?
KREBSBIO has FII holding of 0.50% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.